Get the Daily Brief
Latest Biotech News
KRAS G12C lung cancer competition heats up
Genentech and Roche reported new Phase 3 data for divarasib in previously treated KRAS G12C non-small cell lung cancer, positioning the drug against established KRAS G12C inhibitors. In the...
FDA clears first Treg-based cell therapy for HSCT
The FDA has approved Orca Bio’s Treg-based cell therapy, branded Tregzi, for matched-donor allogeneic hematopoietic stem cell transplantation (HSCT) to reduce the risk of chronic graft-versus-host...
AstraZeneca returns to Chinese partner for new R&D work
AstraZeneca is restarting collaboration activity with CSPC in a deal valued at up to $1.7 billion for drug R&D, according to reporting. The move comes less than six months after AstraZeneca...
Neurostimulation gets FDA-cleared PTSD option for veterans
Neurovalens brought an at-home PTSD neuromodulation device to U.S. veterans after receiving FDA de novo clearance for Modius Spero. The company said the wearable system is designed for daily...
Rare-disease funding: Celea lands $180M to advance deupirfenidone
Celea Therapeutics, a PureTech Health spinout focused on idiopathic pulmonary fibrosis (IPF), raised $180 million to advance deupirfenidone into late-stage testing. The venture funding was backed...
Oral C5aR1 antagonist faces FDA market withdrawal request
The FDA has requested the withdrawal of avacopan (Tavneos), an oral C5a receptor 1 (C5aR1) antagonist, according to a case report reviewing its uncertain future. ChemoCentryx originally discovered...
Genome reanalysis software scales rare-disease diagnosis
A new open-source automated genomic reanalysis tool called Talos can expand rare-disease diagnostic throughput, according to a study published in Nature Medicine. In tests on 4,735 individuals...
Neuroimmune AI drug discovery collaboration grows
Insilico Medicine and SK Biopharmaceuticals expanded their AI-driven collaboration to identify drug candidates for neuroimmune disorders, supported by a reported up-to-$2.5 million research...
Rare disease M&A: Ipsen buys Memo Therapeutics for BK virus antibody
Ipsen agreed to acquire Memo Therapeutics in a potential up-to-€700 million deal, centered on Memo’s potravitug antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients....
Manufacturing scale and talent: PureTech-style investment meets process capability
Biotech and med-tech sector activity highlighted two supply-chain pressures shaping development timelines: capital for platform execution and the operational capacity to scale manufacturing. In...
KRAS G12C lung cancer head-to-head efficacy
Genentech and Roche said its KRAS G12C inhibitor divarasib delivered statistically significant improvements in overall survival and progression-free survival versus approved therapies in...
FDA clears first neurostimulation device for PTSD
Neurovalens won FDA de novo clearance for Modius Spero, the first FDA-approved neuromodulation device indicated for reducing PTSD symptoms. The wearable is designed for at-home use through...
Precision cell therapy approval for HSCT reduces GVHD risk
Orca Bio’s Tregzi (formerly Orca-T) received U.S. FDA approval as a personalized cell therapy for matched-donor allogeneic HSCT in adults with hematologic malignancies. The therapy is positioned...
Rare disease kidney transplant antiviral M&A accelerates pivotal plan
Ipsen agreed to acquire Memo Therapeutics and its Phase 2-ready monoclonal antibody potravitug for BK virus-associated nephropathy in immune-compromised kidney transplant patients. Ipsen will pay...
Biotech financings surge in H1 2026
Biopharma financing activity accelerated in the first half of 2026, with total capital raised across public, private, and other financings reaching $59.76 billion across 567 deals—more than double...
IPF biotech Celea banks $180M ahead of late-stage deupirfenidone
Celea Therapeutics raised $180 million to advance deupirfenidone, its retooled pirfenidone program for idiopathic pulmonary fibrosis, into late-stage testing. The PureTech spinout said the...
AstraZeneca returns to CSPC for another China R&D collaboration
AstraZeneca is launching a new drug R&D collaboration with CSPC in a deal that could reach up to $1.7 billion, returning to the same Chinese partner within months of a landmark transaction. The UK...
US court blocks Colorado Enbrel price cap
A U.S. District Court judge in Colorado halted a 70% price cap on Amgen’s Enbrel after granting the company’s preliminary injunction. Judge Daniel Domenico said the cap could cause “economic...
Genomics England and Lifebit build a trusted research environment
Genomics England and Lifebit announced a partnership to develop a trusted research environment for work on rare diseases and cancer. The platform will create secure, controlled digital workspaces...
Open-source tool automates rare disease genomic reanalysis
Talos, an open-source genomic reanalysis tool, produced 241 diagnoses when tested on 4,735 unsolved rare disease patient genomes, with more than half of findings attributed to new gene- or...